Impact and cost-effectiveness of current and future tuberculosis diagnostics: The contribution of modelling

International Journal of Tuberculosis and Lung Disease

Volumn 18, Issue 9, 2014, Pages 1012-1018

  Dowdy, David W ^a   Houben, R ^b   Cohen, T ^c   Pai, M ^d   Cobelens, F ^e   Vassall, A ^b   Menzies, N A ^c   Gomez, G B ^e   Langley, I ^f   Squire, S B ^f   White, R ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d MCGILL UNIVERSITY   (Canada)

^e AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

^f LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

Diagnostics; Modelling; Tuberculosis

Indexed keywords

MOXIFLOXACIN; PRETOMANID; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TUBERCULOSTATIC AGENT;

BIOASSAY; CONCEPTUAL FRAMEWORK; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC EQUIPMENT; DIAGNOSTIC PROCEDURE; DRUG SENSITIVITY; GOVERNMENT; HEALTH CARE DELIVERY; HEALTH CARE NEED; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HUMAN; MEDICAL DECISION MAKING; POINT OF CARE TESTING; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS; COST BENEFIT ANALYSIS; ECONOMIC MODEL; ECONOMICS; HEALTH CARE COST; HEALTH CARE PLANNING; MEDICAL RESEARCH; MICROBIAL SENSITIVITY TEST; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; PRACTICE GUIDELINE; PREDICTIVE VALUE; PROGNOSIS; STANDARDS;

ANTITUBERCULAR AGENTS; BACTERIOLOGICAL TECHNIQUES; BIOMEDICAL RESEARCH; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HEALTH PRIORITIES; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, ECONOMIC; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUBERCULOSIS;

EID: 84906689555     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.13.0851     Document Type: Review

References (35)

1. Niemz A, Boyle D S. Nucleic acid testing for tuberculosis at the point-of-care in high-burden countries. Expert Rev Mol Diagn 2012; 12: 687-701.
2. Pai N P, Vadnais C, Denkinger C, Engel N, Pai M. Point-of-care testing for infectious diseases: diversity, complexity, and barriers in low- and middle-income countries. PLOS MED 2012; 9: e1001306.
3. Grosset J H, Singer T G, Bishai W R. New drugs for the treatment of tuberculosis: hope and reality. Int J Tuberc Lung Dis 2012; 16: 1005-1014.
4. Wells W A, Boehme C C, Cobelens F G, et al. Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action. Lancet Infect Dis 2013; 13: 449-458.
5. Steingart K R, Sohn H, Schiller I, et al. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2013; 1: CD009593.
6. Lawn S D, Mwaba P, Bates M, et al. Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. Lancet Infect Dis 2013; 13: 349-361.
7. Lessells R J, Cooke G S, McGrath N, Nicol M P, Newell M L, Godfrey-Faussett P. Impact of a novel molecular TB diagnostic system in patients at high risk of TB mortality in rural South Africa (Uchwepheshe): study protocol for a cluster randomised trial. Trials 2013; 14: 170.
8. Garnett G P, Cousens S, Hallett T B, Steketee R, Walker N. Mathematical models in the evaluation of health programmes. Lancet 2011; 378: 515-525.
9. Dowdy D W, Dye C, Cohen T. Data needs for evidence-based decisions: a tuberculosis modeler's 'wish list'. Int J Tuberc Lung Dis 2013; 17: 866-877.
10. Walker D. Economic analysis of tuberculosis diagnostic tests in disease control: how can it be modelled and what additional information is needed? Int J Tuberc Lung Dis 2001; 5: 1099-1108.
11. Lin H H, Langley I, Mwenda R, et al. A modelling framework to support the selection and implementation of new tuberculosis diagnostic tools. Int J Tuberc Lung Dis 2011; 15: 996-1004.
12. Dowdy D W, O Brien M A, Bishai D. Cost-effectiveness of novel diagnostic tools for the diagnosis of tuberculosis. Int J Tuberc Lung Dis 2008; 12: 1021-1029.
13. World Health Organization. WHO monitoring of Xpert MTB/RIF roll-out. Geneva, Switzerland: WHO, 20114. http://www.who.int/tb/laboratory/mtbrifrollout/ en/index.html. Accessed April 2014.
14. Menzies N A, Cohen T, Lin H H, Murray M, Salomon J A. Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation. PLOS MED 2012; 9: e1001347.
15. Vassall A, van Kampen S, Sohn H, et al. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis. PLOS MED 2011; 8: e1001120.
16. Winetsky D E, Negoescu D M, Demarchis E H, et al. Screening and rapid molecular diagnosis of tuberculosis in prisons in Russia and Eastern Europe: a cost-effectiveness analysis. PLOS MED 2012; 9: e1001348.
17. Meyer-Rath G, Schnippel K, Long L, et al. The impact and cost of scaling up GeneXpert MTB/RIF in South Africa. PLOS ONE 2012; 7: e36966.
18. Andrews J R, Lawn S D, Rusu C, et al. The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis. AIDS 2012; 26: 987-995.
19. Pantoja A, Fitzpatrick C, Vassall A, Weyer K, Floyd K. Xpert MTB/RIF for diagnosis of TB and drug-resistant TB: a cost and affordability analysis. Eur Respir J 2013; 42: 708-720.
20. Pooran A, Pieterson E, Davids M, Theron G, Dheda K. What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa? PLOS ONE 2013; 8: e54587.
21. Andrews J R, Lawn S D, Dowdy D W, Walensky R P. Challenges in evaluating the cost-effectiveness of new diagnostic tests for HIV-associated tuberculosis. Clin Infect Dis 2013; 57: 1021-1026.
22. Pai M. Diagnostics for tuberculosis: what test developers want to know. Expert Rev Mol Diagn 2013; 13: 311-314.
23. Lawn S D, Kerkhoff A D, Wood R. Location of Xpert® MTB/RIF in centralised laboratories in South Africa undermines potential impact. Int J Tuberc Lung Dis 2012; 16: 701.
24. Ginsberg A M. Emerging drugs for active tuberculosis. Semin Respir Crit Care Med 2008; 29: 552-559.
25. Koul A, Arnoult E, Lounis N, Guillemont J, Andries K. The challenge of new drug discovery for tuberculosis. Nature 2011; 469: 483-490.
26. Kik S V, Denkinger C M, Casenghi M, Vadnais C, Pai M. Tuberculosis diagnostics: which target product profiles should be prioritized? Eur Respir J 2014 Apr 2. [Epub ahead of print]
27. Diacon A H, Dawson R, von Groote-Bidlingmaier F, et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012; 380: 986-993.
28. Chang K C, Yew W W, Zhang Y. Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: a systematic review with meta-analyses. Antimicrob Agents Chemother 2011; 55: 4499-4505.
29. Cohen T, Dye C, Colijn C, Williams B, Murray M. Mathematical models of the epidemiology and control of drug-resistant TB. Expert Rev Respir Med 2009; 3: 67-79.
30. Dowdy D W, Basu S, Andrews J R. Is passive diagnosis enough? The impact of subclinical disease on diagnostic strategies for tuberculosis. Am J Respir Crit Care Med 2013; 187: 543-551.
31. Barter D M, Agboola S O, Murray M B, Bärnighausen T. Tuberculosis and poverty: the contribution of patient costs in sub-Saharan Africa - a systematic review. BMC Public Health 2012; 12: 980.
32. Ukwaja K N, Modebe O, Igwenyi C, Alobu I. The economic burden of tuberculosis care for patients and households in Africa: a systematic review. Int J Tuberc Lung Dis 2012; 16: 733-739.
33. Tanimura T, Jaramillo E, Weil D, Raviglione M, Lönnroth K. Financial burden for tuberculosis patients in low- and middle-income countries: a systematic review. Eur Respir J 2014; 43: 1763-1775.
34. Roetzer A, Diel R, Kohl T A, et al. Whole genome sequencing versus traditional genotyping for investigation of a Mycobacterium tuberculosis outbreak: a longitudinal molecular epidemiological study. PLOS MED 2013; 10: e1001387.
35. Huf G, Kritski A. Evaluation of the clinical utility of new diagnostic tests for tuberculosis: the role of pragmatic clinical trials. J Bras Pneumol 2012; 38: 237-245.